Unlike other tumor suppressors, such as APC, which are usually inactivated early in CRC development, TP53 mutations are typically acquired later in the adenoma–carcinoma sequence, contributing to the transition from a benign adenoma to an invasive carcinoma [88,90]. Here, APC is linked to adenoma.